|
Mutation Information
|
Mutation Site
|
M204V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.T184S+rt.L180M;rt.M204V+rt.M204I+rt.L180M;rt.M204V+rt.L180M;rt.M204V+rt.L180M+rt.V173L |
|
Relevant Drug
|
lamivudine (LAM);adefovir dipivoxil (ADV);tenofovir (TDF) |
|
Country
|
Italy |
Literature Information
|
PubMed PMID
|
25742145
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2015 |
|
Journal
|
The new microbiologica |
|
Title
|
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine. |
|
Author
|
De Francesco MA,Gargiulo F,Spinetti A,Zaltron S,Giagulli C,Caccuri F,Castelli F,Caruso A |
|
Evidence
|
The main mutations observed were associated with LAM resistance: rtM204V/I alone (7/17, 41%) or in association with its compensatory mutations, rtL180M as double mutation (3/17, 17.6%) and rt V173 as triple mutation (2/17,11.7%).
|
|
|
HBV Mutation Detail Information